Reviva to Participate in the UBS Global Healthcare Conference

Rhea-AI Summary

Reviva Pharmaceuticals (NASDAQ: RVPH), a late-stage pharmaceutical company focused on central nervous system, inflammatory and cardiometabolic diseases, has announced its participation in the UBS Global Healthcare Conference. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will engage in a fireside chat at the conference, which is scheduled for November 11-14, 2024, in Rancho Palos Verdes, CA. The presentation is specifically scheduled for Thursday, November 14, 2024, at 8:00 a.m. PT.

News Market Reaction – RVPH

-3.03%

-3.03% Session move

In the trading session that priced this news, RVPH declined 3.03%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place November 11-14, 2024, in Rancho Palos Verdes, CA.

UBS Global Healthcare Conference
Format: Fireside chat
Date: Thursday, November 14, 2024
Time: 8:00 a.m. PT
Location: Rancho Palos Verdes, CA
Webcast Link: Click Here

About Reviva 
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD 
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

When is Reviva Pharmaceuticals (RVPH) presenting at the UBS Global Healthcare Conference 2024?

Reviva Pharmaceuticals will present on Thursday, November 14, 2024, at 8:00 a.m. PT at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA.

What type of presentation will RVPH deliver at the UBS Healthcare Conference?

RVPH will participate in a fireside chat format presentation at the conference.

What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?

Reviva Pharmaceuticals focuses on developing therapies for central nervous system (CNS), inflammatory and cardiometabolic diseases.

Where is the 2024 UBS Global Healthcare Conference being held?

The UBS Global Healthcare Conference is being held in Rancho Palos Verdes, California, from November 11-14, 2024.